JP2022530068A5 - - Google Patents

Info

Publication number
JP2022530068A5
JP2022530068A5 JP2021563064A JP2021563064A JP2022530068A5 JP 2022530068 A5 JP2022530068 A5 JP 2022530068A5 JP 2021563064 A JP2021563064 A JP 2021563064A JP 2021563064 A JP2021563064 A JP 2021563064A JP 2022530068 A5 JP2022530068 A5 JP 2022530068A5
Authority
JP
Japan
Prior art keywords
seq
protein
sequence
composition according
replaced
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021563064A
Other languages
English (en)
Japanese (ja)
Other versions
JP7603612B2 (ja
JP2022530068A (ja
Filing date
Publication date
Priority claimed from GBGB1905810.6A external-priority patent/GB201905810D0/en
Application filed filed Critical
Publication of JP2022530068A publication Critical patent/JP2022530068A/ja
Publication of JP2022530068A5 publication Critical patent/JP2022530068A5/ja
Application granted granted Critical
Publication of JP7603612B2 publication Critical patent/JP7603612B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021563064A 2019-04-25 2020-03-04 治療法 Active JP7603612B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB1905810.6A GB201905810D0 (en) 2019-04-25 2019-04-25 Method of treatment
GB1905810.6 2019-04-25
GBGB2000955.1A GB202000955D0 (en) 2019-04-25 2020-01-22 Method of treatment
GB2000955.1 2020-01-22
PCT/EP2020/055741 WO2020216513A1 (en) 2019-04-25 2020-03-04 Method of treatment

Publications (3)

Publication Number Publication Date
JP2022530068A JP2022530068A (ja) 2022-06-27
JP2022530068A5 true JP2022530068A5 (cg-RX-API-DMAC7.html) 2023-03-13
JP7603612B2 JP7603612B2 (ja) 2024-12-20

Family

ID=66810336

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021563064A Active JP7603612B2 (ja) 2019-04-25 2020-03-04 治療法

Country Status (10)

Country Link
US (1) US20220211810A1 (cg-RX-API-DMAC7.html)
EP (1) EP3958974A1 (cg-RX-API-DMAC7.html)
JP (1) JP7603612B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220018963A (cg-RX-API-DMAC7.html)
CN (1) CN114072206B (cg-RX-API-DMAC7.html)
AU (1) AU2020263709A1 (cg-RX-API-DMAC7.html)
CA (1) CA3137240A1 (cg-RX-API-DMAC7.html)
GB (2) GB201905810D0 (cg-RX-API-DMAC7.html)
IL (1) IL287250A (cg-RX-API-DMAC7.html)
WO (1) WO2020216513A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202218084D0 (en) * 2022-12-01 2023-01-18 Volution Immuno Pharmaceuticals Sa Fusion proteins
WO2024238859A1 (en) * 2023-05-16 2024-11-21 Regenxbio Inc. Vectorized c5 inhibitor agents and administration thereof
GB202408081D0 (en) 2024-06-06 2024-07-24 Volution Immuno Pharmaceuticals Sa Methods of removing impurities

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7884188B2 (en) 2003-06-02 2011-02-08 Varleigh Immuno Pharmaceuticals (Vip) Ltd Complement inhibitors
GB0518443D0 (en) 2005-09-09 2005-10-19 Evolutec Ltd Method of treating myasthenia gravis
GB0617734D0 (en) 2006-09-08 2006-10-18 Evolutec Ltd Method of treating peripheral nerve disorders
EP2061501B1 (en) 2006-09-08 2015-04-08 Volution Immuno Pharmaceuticals SA Method of treating respiratory disorders
WO2008113834A2 (en) 2007-03-22 2008-09-25 Novartis Ag C5 antigens and uses thereof
US8563521B2 (en) * 2007-06-21 2013-10-22 Technische Universitat Munchen Biological active proteins having increased in vivo and/or in vitro stability
GB0802116D0 (en) * 2008-02-05 2008-03-12 Natural Enviromental Res Counc Treatment
GB0906779D0 (en) * 2009-04-20 2009-06-03 Natural Environment Res Council Composition
CA2785612C (en) * 2010-01-08 2019-09-10 Varleigh Immuno Pharmaceuticals (Vip) Ltd. Ev576 for use in the treatment of viral infections of the respiratory tract
GB201401453D0 (en) * 2014-01-28 2014-03-12 Univ Birmingham Transmucosal and transepithelial drug delivery system
GB201410116D0 (en) * 2014-06-06 2014-07-23 Volution Immuno Pharmaceuticals Sa Method of treatment
WO2016198133A1 (en) 2015-06-08 2016-12-15 Volution Immuno Pharmaceuticals Sa Ornithodoros moubata complement inhibitor for use in the treatment of acute graft versus host disease
EP3359566A1 (en) 2015-10-07 2018-08-15 Alexion Pharmaceuticals, Inc. A method for treating age-related macular degeneration in a patient
MX2018016046A (es) * 2016-06-27 2019-05-02 Achillion Pharmaceuticals Inc Quinazolina y compuestos indol para tratar trastornos medicos.
EP3570888A1 (en) * 2017-03-03 2019-11-27 MacRegen, Inc. Treatment of age-related macular degeneration and other eye diseases with one or more therapeutic agents
JP7209637B2 (ja) * 2017-04-21 2023-01-20 ヴォリューション イミュノ ファーマシューティカルズ エスエイ 自己免疫性水疱症の治療のためのコバーシン
GB201706406D0 (en) * 2017-04-21 2017-06-07 Volution Immuno Pharmaceuticals Sa Method of treatment
CN110831617A (zh) * 2017-04-21 2020-02-21 沃卢申伊缪诺制药公司 用于治疗瘢痕性眼部发炎性病症的Coversin
JP7629394B2 (ja) * 2018-09-10 2025-02-13 ヴォリューション イミュノ ファーマシューティカルズ エスエイ リウマチ性疾患の治療に使用するためのコバーシン
JP2023503776A (ja) * 2019-09-27 2023-02-01 ヴォリューション イミュノ ファーマシューティカルズ エスエイ 造血幹細胞移植後の血栓性微小血管症(hsct-tma)の治療方法

Similar Documents

Publication Publication Date Title
JP6854266B2 (ja) 抗体製剤および方法
JP7045333B2 (ja) 操作されたFcコンストラクトに関する組成物及び方法
EP3576789B1 (en) MONOMERIC HUMAN IgG1 Fc AND BISPECIFIC ANTIBODIES
JP6585720B2 (ja) 眼疾患治療のペプチド及びこれを含む眼疾患治療用組成物
TWI773695B (zh) 抗C1s抗體及其使用方法
JP2021527656A5 (cg-RX-API-DMAC7.html)
JP2023040169A5 (cg-RX-API-DMAC7.html)
JP7477457B2 (ja) C3結合薬及びその使用方法
TW200904471A (en) Prevention and the treatment of complement-associated eye conditions
US20230192887A1 (en) Engineered anti-her2 bispecific proteins
JP2021534220A5 (cg-RX-API-DMAC7.html)
TW201243049A (en) Multi-specific antigen-binding molecule having alternative function to function of blood coagulation factor viii
HUE032654T2 (en) scFv antibodies that cross the epithelial and / or endothelial layers
JP2023545707A5 (cg-RX-API-DMAC7.html)
JP2021511030A5 (cg-RX-API-DMAC7.html)
KR102613963B1 (ko) Ace2 결합력이 감소된 코로나바이러스 유래 수용체 결합 도메인 변이체 및 이를 포함하는 백신 조성물
CN110156890B (zh) Semaphorin7A单克隆抗体及其在制备用于治疗炎症疾病药物方面的应用
US20240279324A1 (en) Multispecific antagonists
JP2024546129A5 (cg-RX-API-DMAC7.html)
JP7606173B2 (ja) I型インターフェロンの中和型Fc融合タンパク質及びその使用
WO2024114641A1 (en) C5/vegf bispecific binding molecules
CN103172751B (zh) PA4-Fc的融合蛋白及其编码基因与应用
RU2802307C2 (ru) C3-связывающие агенты и способы их применения
HK40126782A (en) C5/vegf bispecific binding molecules
TW202605146A (zh) IgE蛋白酶及其用途